Literature DB >> 11713224

Identification of a Wnt/beta-catenin signaling pathway in human thyroid cells.

K Helmbrecht1, A Kispert, R von Wasielewski, G Brabant.   

Abstract

beta-Catenin is a structural component of the adherens junctions. Outside the adherens junctions a complex consisting of glycogen synthase kinase 3beta, the tumor suppressor adenomatous polyposis coli, and axin constantly targets beta-Catenin for degradation to keep levels of free beta-Catenin low. Free beta-Catenin is able to bind to transcription factors of the T cell factor/lymphoid-enhancing factor family and to stimulate transcription of target genes. This signaling function of beta-Catenin is activated by extracellular Wnt factors that bind to Frizzled receptors and induce inhibition of beta-Catenin degradation. By RT-PCR and subcloning, we observed the expression of five Wnt factors, three members of the Frizzled receptor family, and all known Disheveled isoforms in thyroid cells. Immunoprecipitation studies demonstrated the formation of the complex targeting beta-Catenin for degradation. Introduction of a degradation resistant beta-Catenin into the thyroid carcinoma cell line WRO induced appearance of monomeric beta-Catenin as shown by size fractionation and nuclear beta-Catenin immunostaining. Reporter gene assays demonstrated a stimulation of T cell factor/lymphoid-enhancing factor-mediated transcription in these cells. In ARO cells, a thyroid carcinoma cell line carrying a mutated adenomatous polyposis coli gene, monomeric beta-Catenin and nuclear immunostaining were observed. In summary, our data indicate that elements of the Wnt signaling pathway are expressed in thyroid cells and that this pathway is functionally active.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713224     DOI: 10.1210/endo.142.12.8554

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Authors:  Dang Vu-Phan; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; Max S Wicha; Ronald J Koenig
Journal:  Endocr Relat Cancer       Date:  2013-09-11       Impact factor: 5.678

2.  Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

Authors:  Carmen J Tartari; Carla Donadoni; Elisa Manieri; Luca Mologni; Pamela Della Mina; Antonello Villa; Carlo Gambacorti-Passerini
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

3.  Wnt-independent role of β-catenin in thyroid cell proliferation and differentiation.

Authors:  Ana Sastre-Perona; Pilar Santisteban
Journal:  Mol Endocrinol       Date:  2014-03-19

Review 4.  beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas.

Authors:  S Rezk; R K Brynes; V Nelson; M Thein; N Patwardhan; A Fischer; A Khan
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

5.  Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway.

Authors:  Gang Chen; Qiqin Jiang; Zhenhui You; Jin Yao; Lunpan Mou; Xu Lin; Xiaoyan Shen; Tingting You; Qiang Lin; Junping Wen; Lixiang Lin
Journal:  Mol Biol Rep       Date:  2009-09-15       Impact factor: 2.316

6.  Convergence of 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A and glycogen synthase kinase-3beta/beta-catenin signaling in corpus luteum progesterone synthesis.

Authors:  Lynn Roy; Claudia A McDonald; Chao Jiang; Dulce Maroni; Anthony J Zeleznik; Todd A Wyatt; Xiaoying Hou; John S Davis
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

7.  Role of the wnt pathway in thyroid cancer.

Authors:  Ana Sastre-Perona; Pilar Santisteban
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-29       Impact factor: 5.555

8.  Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.

Authors:  Kartick C Pramanik; Neel M Fofaria; Parul Gupta; Alok Ranjan; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Oncotarget       Date:  2015-05-10

9.  LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.

Authors:  Gregory Michelotti; Xiaoyin Jiang; Julie Ann Sosa; Anna Mae Diehl; Brittany Bohinc Henderson
Journal:  Oncotarget       Date:  2015-10-27

10.  Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.

Authors:  Yea Eun Kang; Jin-Man Kim; Koon Soon Kim; Joon Young Chang; Mingyu Jung; Junguee Lee; Shinae Yi; Hyeon Woo Kim; Jung Tae Kim; Kyungmin Lee; Min Jeong Choi; Seul Ki Kang; Seong Eun Lee; Hyon-Seung Yi; Bon Seok Koo; Minho Shong
Journal:  Oncotarget       Date:  2017-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.